Table 3.
Prognostic factors for OS in 678 patients with Stage I–III GC undergoing curative resection
| Characteristic | Univariate analysis HR (95% CI) | P-value | Multivariate analysis HR (95% CI) | P-value |
|---|---|---|---|---|
| Age, years | 1.320 (0.967–1.802) | 0.08 | ||
| <60 | ||||
| ≥60 | ||||
| Sex | 1.066 (0.767–1.479) | 0.71 | ||
| Male | ||||
| Female | ||||
| Tumor location | 0.799 (0.669–0.956) | 0.01 | 0.898 (0.741–1.088) | 0.27 |
| Upper third | ||||
| Middle third | ||||
| Lower third | ||||
| Tumor size, cm | 1.780 (1.302–2.433) | <0.001 | 1.087 (0.770–1.534) | 0.64 |
| <5 | ||||
| ≥5 | ||||
| Histological grade | 1.488 (0.963–2.297) | 0.07 | ||
| Well-differentiated | ||||
| Poorly differentiated | ||||
| Histological type | 1.043 (0.815–1.335) | 0.74 | ||
| Intestinal type | ||||
| Diffuse type | ||||
| Mixed type | ||||
| TNM stage | 3.761 (2.704–5.232) | <0.001 | 3.878 (2.665–5.643) | ,0.001 |
| I | ||||
| II | ||||
| III | ||||
| Adjuvant chemotherapy | 1.224 (0.830–1.803) | 0.31 | ||
| Yes | ||||
| No | ||||
| CEA | 1.668 (1.174–2.370) | 0.004 | 1.177 (0.808–1.715) | 0.40 |
| Normal | ||||
| Elevated | ||||
| CA19-9 | 1.736 (1.127–2.676) | 0.01 | 1.383 (0.889–2.151) | 0.15 |
| Normal | ||||
| Elevated | ||||
| CA72-4 | 1.216 (0.824–1.795) | 0.32 | ||
| Normal | ||||
| Elevated | ||||
| VEGF expression | 1.485 (1.047–2.108) | 0.03 | 1.252 (0.862–1.818) | 0.24 |
| Positive | ||||
| Negative | ||||
| HER2 expression | 1.419 (1.033–1.948) | 0.03 | 1.554 (1.106–2.182) | 0.01 |
| Positive | ||||
| Negative |
Abbreviations: CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CI, confidence interval; GC, gastric cancer; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; TNM, tumor–node–metastasis; VEGF, vascular endothelial growth factor.